Your browser doesn't support javascript.
loading
SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies.
Beukenhorst, Anna L; Koch, Clarissa M; Hadjichrysanthou, Christoforos; Alter, Galit; de Wolf, Frank; Anderson, Roy M; Goudsmit, Jaap.
Afiliação
  • Beukenhorst AL; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. anna.beukenhorst@leydenlabs.com.
  • Koch CM; Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. anna.beukenhorst@leydenlabs.com.
  • Hadjichrysanthou C; Leyden Laboratories BV, Amsterdam, The Netherlands. anna.beukenhorst@leydenlabs.com.
  • Alter G; Leyden Laboratories BV, Amsterdam, The Netherlands.
  • de Wolf F; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
  • Anderson RM; Ragon Institute of MGH MIT and Harvard, Cambridge, MA, USA.
  • Goudsmit J; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
Eur J Epidemiol ; 38(3): 237-242, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36738380
ABSTRACT
Neither vaccination nor natural infection result in long-lasting protection against SARS-COV-2 infection and transmission, but both reduce the risk of severe COVID-19. To generate insights into optimal vaccination strategies for prevention of severe COVID-19 in the population, we extended a Susceptible-Exposed-Infectious-Removed (SEIR) mathematical model to compare the impact of vaccines that are highly protective against severe COVID-19 but not against infection and transmission, with those that block SARS-CoV-2 infection. Our analysis shows that vaccination strategies focusing on the prevention of severe COVID-19 are more effective than those focusing on creating of herd immunity. Key uncertainties that would affect the choice of vaccination strategies are (1) the duration of protection against severe disease, (2) the protection against severe disease from variants that escape vaccine-induced immunity, (3) the incidence of long-COVID and level of protection provided by the vaccine, and (4) the rate of serious adverse events following vaccination, stratified by demographic variables.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article